6-week Study Treatment to Evaluate the Safety and Effectiveness of AZD2066 in Patients With Major Depressive Disorder

Stopped early · Phase 2 · Has a placebo group

Conditions studied: Major Depressive Disorder

In brief

This is a 6-week study treatment to evaluate the safety and effectiveness of AZD2066 in patients with major depressive disorder.

Key facts

Study ID: NCT01145755
Run by: AstraZeneca
People needed: 131
Starts: 2010-05-01
Expected to finish: 2010-11-01
Last updated by the study team: 2012-10-03

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

Provision of signed, written, and dated Informed Consent
Documented primary clinical diagnosis of Major Depressive Disorder

You may not qualify if…

Patients with a secondary psychiatric disorder including bipolar disorder, psychotic disorders (i.e. schizophrenia, schizoaffective disorder, depression with psychotic features), GAD and social anxiety disorder
Patients whose current episode of depression started less than 4 weeks before enrollment
History of inadequate response of antidepressants during current depressive episode

Where it is running

Research Site — Garden Grove, California, United States
Research Site — San Diego, California, United States
Research Site — Jacksonville, Florida, United States
Research Site — Atlanta, Georgia, United States
Research Site — Rockville, Maryland, United States
Research Site — Boston, Massachusetts, United States
Research Site — Cedarhurst, New York, United States
Research Site — Rochester, New York, United States
Research Site — Portland, Oregon, United States
Research Site — Memphis, Tennessee, United States
Research Site — Friendswood, Texas, United States
Research Site — Bellevue, Washington, United States
Research Site — Seattle, Washington, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.